AC Immune and Biogen Partner to Develop TDP-43 Imaging Biomarkers

Swiss biopharmaceutical company AC Immune has entered into a research and development collaboration with biotechnology company Biogen to develop PET radioligands for TDP-43, a protein present in pathological  aggregates in the majority of cases of ALS and FTD.  AC immune will leverage its chemistry technology platform to design small molecules selective for TDP-43, and jointly with Biogen, these will be further developed and clinically validated for use as PET tracers for TDP-43 proteinopathies (see April 2016 news).

Click here to read more.

disease-als disease-ftd topic-clinical topic-newmethods topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail